<DOC>
	<DOCNO>NCT00670527</DOCNO>
	<brief_summary>The objective trial ass value 18F-choline PET/CT detection regional lymph node metastasis prostate cancer . In addition , investigator want evaluate whether 18F-choline PET/CT replace lymphadenectomy stag prostate cancer .</brief_summary>
	<brief_title>18F Fluorocholine FCH Positron Emission Tomography ( PET ) /Computed Tomography ( CT ) Detection Prostate Cancer Lymph Nodes Metastases</brief_title>
	<detailed_description>The purpose prospective trail improve stag patient prostate cancer . The investigator focus group patient newly diagnose prostate cancer , specifically one intermediate high risk disseminate prostate cancer . The aim improve stag replace traditional invasive method , lymphadenectomy , rather low sensitivity non-invasive method , 18F-choline PET/CT presumably superior sensitivity . The treatment patient prostate cancer rely stage disease . Patients disseminated prostate cancer incurable treat palliatively . In contrast , patient localized prostate cancer offer curative therapy . Hence , stage prostate cancer crucial choice treatment . The potential benefit - The patient avoid surgical trauma include complication convalescent period . - The accuracy prostate cancer stag improve , potential good survival . The patient 18F-choline PET/CT scan prior lymphadenectomy , result 18F-choline PET/CT blind surgeon . The endpoint trail comparison 18F-choline PET/CT histopathological investigation regional lymph node prostate . Assuming prevalence metastasise prostate cancer 20 % true ( unknown ) sensitivity FCH PET/CT 95 % , 205 patient sufficient show sensitivity FCH PET/CT great 80 % power 80 % significance level 5 % . The size confidence interval specificity FCH PET/CT expect become reasonable small . In opposition lymphadenectomy , FCH PET/CT result may point metastasis neighbour region give additional benefit FCH PET/CT justify test level sensitivity 80 % . '' Accordingly 205 patient include 2Â½ year . The first patient include January 2008 . Interim analyse do 25 , 50 100 patient .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Choline</mesh_term>
	<criteria>Patients biopsy confirm prostate cancer awaits curative treatment An elevated level prostatespecific antigen PSA &gt; 10 ng/mL ( nanogram per milliliter ) or/and A Gleason score &gt; 6 or/and A TNM stag T3 Patients withdraw inform consent . Patients bone scan indicate metastatic prostate cancer . Patients TNM stage T4 In case detect patient obvious major illness e.g . lung cancer , patient refer relevant treatment . Depending illness might exclude study .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>[ 18F ] Fluorocholine PET/CT</keyword>
	<keyword>FCH</keyword>
	<keyword>lymph node metastasis</keyword>
	<keyword>stag</keyword>
	<keyword>sensitivity</keyword>
	<keyword>specificity</keyword>
	<keyword>PROPET</keyword>
</DOC>